WSIT WSIT-RG-0053

WSIT Reference Guide — Melatonin Supplements

An industry reference for melatonin supplements covering mechanisms, dosage forms, quality parameters, non-medical service boundaries, and regulatory differences across jurisdictions.

1. Classification and Scope

1.1 WSIC Classification

Note: This classification is based on WSIC V1.0. This section will be updated when the classification system is revised; the main body of the document will remain unaffected.

Item Details
Primary category Category 3: Consumer Products and Content
Secondary category 3.1 Functional Foods
Tertiary category 3.1.1 Single-Ingredient Supplements

1.2 Product Boundary

A melatonin supplement is a functional-food or dietary-supplement product taken orally, containing exogenous melatonin—chemically synthesized or biologically extracted—as its single active ingredient, and primarily used in circadian-rhythm regulation settings.

This guide covers the following product forms:

Form Technical characteristics Common use cases
Tablets Metered compression provides relatively high dosage accuracy Routine personal use
Gummies High palatability and generally better adherence Younger consumer groups
Oral liquids or drops Relatively rapid absorption and convenient dose adjustment Users requiring smaller dosage increments
Powders or powdered beverages Flexible preparation Can be added to everyday food or drinks

The following are outside the scope of this guide:

  • Products intended to treat disease and approved through a pharmaceutical registration pathway; these are classified as pharmaceuticals under WSIC
  • Multi-ingredient products in which melatonin is only one of several active ingredients; these are classified as compounded or formulated functional foods
  • Ordinary foods not primarily intended for circadian-rhythm regulation

Overview of regulatory differences by jurisdiction (see Section 5.2 for details):

Jurisdiction Regulatory status Core rule
Mainland China Health-food ingredient Included in the Catalogue of Health Food Ingredients; ingredient purity ≥99.5%; recommended daily intake for filed products is 1–3 mg
United States Dietary supplement Regulated as a dietary supplement; no FDA premarket approval is required, and businesses are responsible for product quality and compliant claims
European Union Varies substantially by member state Prolonged-release products are generally regulated as prescription medicines; immediate-release products may be sold as dietary supplements in some member states
Australia Registered medicine Products require authorization from the Therapeutic Goods Administration before marketing
Canada Natural health product A product license is required; the recommended adult daily intake generally ranges from 0.5 to 10 mg

Because regulatory status varies by jurisdiction, the same ingredient may be classified as either a functional food or a pharmaceutical. This guide covers only products regulated as functional foods or dietary supplements.

1.3 Related Tagging System

This section is the sole consolidated location for tag codes. Chinese names are used elsewhere in the source document; only this table needs to be updated when the tagging system changes.

Tag type Tag code Tag name Description
Non-Sleep Intervention Method tag (NSIM) IM9 Biological-rhythm intervention The core mechanism is based on circadian phase adjustment
Scenario tag S1.2 Self-management at home —
Scenario tag S1.6 Travel and mobile sleep —
Population tag P-Shift Shift workers and people with atypical schedules —
Population tag P-Elderly Older adults —
Value-chain position tag M Midstream integration and operations —

Definitions of population tags are provided in the scenario tagging system document.

2. Core Ingredient and Mechanisms of Action

2.1 Physiological Role of Endogenous Melatonin

Melatonin is an endogenous hormone secreted by the pineal gland. Its chemical name is N-acetyl-5-methoxytryptamine. Its core physiological role is to participate in circadian phase regulation and convey environmental light–dark cycle signals:

  • Secretion increases in darkness and participates in the physiological processes involved in sleep initiation
  • Secretion is suppressed by light, helping the body maintain wakefulness

Melatonin secretion changes dynamically with age: it reaches its highest level in early childhood, gradually declines through adulthood, and is substantially lower in older age.

2.2 Pathways of Exogenous Supplementation

Research into the mechanisms of exogenous melatonin supplements focuses mainly on the following areas:

Level of action Mechanism Research status
MT1/MT2 receptor binding Exogenous melatonin binds to melatonin receptors in the suprachiasmatic nucleus (SCN) and participates in dark-signal transmission Mechanism is well established in basic research
Phase adjustment Depending on the timing of intake, melatonin may advance or delay circadian phase Existing findings are relatively consistent
Sleep-related regulation Participates in physiological processes related to sleep initiation; its direct sedative effect is relatively weak Existing findings differ to some extent

2.3 Characteristics of Action

Characteristic Description
Pharmacokinetics Peak plasma concentration generally occurs about 30–60 minutes after oral administration, with substantial individual variation
Core target The circadian regulatory system, including the suprachiasmatic nucleus, rather than direct central nervous system sedation
Main research settings Circadian displacement, such as jet lag and shift work, rather than sleep problems in general

2.4 Current Research Evidence

The quality of evidence for exogenous melatonin differs across use cases. Findings are generally based on specific populations and dosages and are not universally applicable:

  • Jet lag: findings are relatively consistent, with comparatively stronger evidence for circadian adjustment when travelling eastward across two to five time zones
  • Sleep-onset latency: meta-analyses in healthy populations suggest that exogenous melatonin may shorten sleep-onset latency to some degree, although results vary among studies
  • Shift-work sleep: evidence concerning daytime sleep in shift workers is of low quality; some studies suggest a possible increase in daytime sleep duration
  • Persistent difficulty initiating sleep: relevant evidence is limited and the observed effect is relatively small

2.5 Boundary with Pharmaceutical Products

Dimension Food or dietary supplement (this category) Pharmaceutical product
Regulatory pathway Filing, notification, or other jurisdiction-specific pathway Pharmaceutical registration and approval
Permitted claims Strictly limited by local law and may not claim to treat disease Approved disease-treatment indications may be stated on the label
Dosage range Limited by local regulations Used as directed by a physician, potentially across a broader dosage range
Method of use Purchased and used by the consumer Used under the direction of a physician or pharmacist

3. Technical Selection Reference

The following parameters are reference ranges for global industry procurement, quality control, and product selection. They are not mandatory standards. Product technical documentation and the laws of the jurisdiction in which the product is marketed take precedence.

3.1 Core Technical Parameters

Parameter Common global industry range Description
Active ingredient per serving 0.5–10 mg Permitted limits differ significantly by jurisdiction and must comply with local law
Ingredient purity Mainstream ingredients are generally ≥99.5% pure High purity is a common industry requirement; the applicable local standard governs the exact threshold
Common labeled timing 30–60 minutes before bedtime Commonly stated on marketed products; actual use is governed by the product instructions
Duration covered by research Existing research focuses mainly on short-term use Evidence on the safety of long-term continuous use remains insufficient

3.2 Ingredient Sources

Ingredient type Production process Industry characteristics
Chemical synthesis Multi-step synthesis from chemical feedstocks Controllable cost and stable purity; the predominant source in the global market
Biological extraction Extraction and purification from plant or animal material Higher ingredient cost and limited output

3.3 Comparison of Dosage Forms

Dosage form Technical characteristics Reference use cases Considerations
Immediate release Rapid absorption and short time to peak plasma concentration Sleep-timing adjustment and cross-time-zone travel Relatively large fluctuation in plasma concentration
Prolonged release Slow ingredient release and longer maintenance of plasma concentration Circadian adjustment related to sleep maintenance May prolong next-day residual effects
Gummies Palatable and generally easy to take consistently Younger consumer groups Ingredient accuracy varies considerably and excipient composition is relatively complex
Drops or sprays Flexible dosage adjustment and relatively rapid absorption Users requiring smaller dosage increments Dosage accuracy and product stability require attention

3.4 Quality-Control Reference Points

Quality dimension Industry selection reference
Content consistency Public testing in multiple markets has found differences between actual and labeled content in some products; third-party test reports may be reviewed during selection
Ingredient purity Review the source and purity test report and confirm compliance with local ingredient-quality standards
Third-party quality certification Certifications under international third-party systems such as NSF and USP may be considered
Excipients and additives Gummies, oral liquids, and similar products may contain sugar, colors, preservatives, and other excipients that must comply with applicable food-additive standards
Stability Review stability over the stated shelf life; melatonin may degrade when exposed to light or high temperatures

4. Boundaries for Non-Medical Applications

This section defines information-communication boundaries for non-medical sleep-service providers. It does not constitute consumer usage advice.

4.1 Self-Management at Home

In non-medical service settings, providers may offer only publicly available information. Such information does not replace product instructions or professional medical advice:

  • For circadian adjustment across time zones, providers may explain the research background concerning melatonin and circadian rhythm while making clear that actual use must follow the product instructions
  • For shifts in daily schedule, providers may explain information related to phase adjustment while emphasizing the foundational roles of schedule management and appropriately timed light exposure
  • Providers should clearly tell clients to use the low end of the dosage stated on the product label as their reference point and to avoid exceeding the labeled dosage on their own

4.2 Travel and Mobile Sleep

  • During cross-time-zone travel, melatonin may be presented as one informational option supporting circadian adjustment; existing studies generally cover use from the day of travel through two to four nights after arrival
  • Providers should make clear that circadian adjustment requires a combination of appropriately timed light exposure, schedule planning, and other measures; a supplement alone cannot produce complete adaptation

4.3 Conduct Outside the Service Boundary

The following conduct exceeds the reasonable boundary of non-medical sleep services and should be strictly avoided:

  • Recommending a specific melatonin brand or giving preference-based purchasing directions
  • Designing an individualized supplement regimen based on a client's sleep condition; this is similar in nature to diagnosis and prescribing and exceeds the scope of non-medical services
  • Making definitive promises such as “guaranteed to work” or “solves sleep problems”; these statements create a risk of misleading advertising
  • Advising clients to take the product continuously every day over the long term; evidence concerning long-term safety remains insufficient
  • Bundling melatonin supplements into a service package as a sales requirement

5. Compliance and Risk Notices

5.1 General Compliance Principles

Item Description
Outside the scope of this guide Pharmaceutical-grade melatonin products and prescription melatonin preparations
What this guide does not provide Diagnosis or treatment advice for insomnia, sleep disorders, circadian-rhythm disorders, or other diseases
Product positioning Melatonin supplements may be used only in non-medical settings related to circadian-rhythm regulation and do not replace a healthy lifestyle
Situations requiring medical referral Persistent severe sleep problems, suspected sleep disorders, substantial daytime functional impairment, and similar concerns

When referral indicators are present, non-medical sleep-service providers should not make a medical determination and should advise the person to seek care from a qualified medical institution.

5.2 Regulatory Differences in Major Jurisdictions

Melatonin's regulatory status varies substantially worldwide. Product development, manufacturing, labeling, claims, and sales must comply with the laws in force where the product is marketed:

Jurisdiction Regulatory status Core impact on development and promotion
Mainland China Health-food ingredient managed through a filing system; State Administration for Market Regulation (SAMR) May be used only in health foods that have completed the required filing; permitted functional claims are strictly limited to “improving sleep”; ingredient purity must be ≥99.5%; recommended daily intake is 1–3 mg
United States Dietary supplement; U.S. Food and Drug Administration (FDA) No FDA premarket approval is required; businesses are responsible for product quality and compliant claims; disease-treatment claims are prohibited
European Union Requirements differ substantially among member states Prolonged-release melatonin is generally regulated as a prescription medicine; immediate-release melatonin may be sold as a dietary supplement in some member states, commonly at daily doses no greater than 2 mg, subject to current national law
Australia Medicine; Therapeutic Goods Administration (TGA) Pharmaceutical registration or authorization is required before marketing
Canada Natural health product; Health Canada A product license is required; the recommended adult daily intake generally ranges from 0.5 to 10 mg

Cross-border compliance notice: the same product may be subject to entirely different regulatory requirements in different jurisdictions. Claims and promotional wording should not be copied from one jurisdiction to another. Cross-border e-commerce must satisfy the requirements of both the place of origin and the destination market.

5.3 Prohibited Promotional Claims

Risk category General global compliance point
Medicalized wording Use of terms such as “treat,” “cure,” “therapeutic effect,” or “course of treatment,” or reference to diagnosed diseases, creates legal risk in most jurisdictions
Claims beyond authorization Functional claims must remain within the scope permitted by the regulator where the product is marketed; broader claims commonly create legal risk
Absolute claims Definitive promises such as “works,” “guaranteed,” “cures,” or “solves” commonly constitute misleading advertising
Misleading explanation Directly equating the physiological role of endogenous melatonin with the effect of an exogenous supplement can mislead consumers

Comparison of compliant wording:

Suggested wording Wording to avoid
Contains melatonin and may be considered in circadian-adjustment settings Treats insomnia; improves sleep quality
An optional aid for circadian adjustment during cross-time-zone travel Natural sleeping pill; fall asleep quickly
One informational option for schedule adjustment Calms the mind and promotes sleep; an instant-sleep solution

5.4 Suggested Product Label and Instruction Information

In addition to satisfying the laws where the product is marketed, a melatonin supplement label should include the following risk information where appropriate:

  • Clearly state the product category: this product is a food or dietary supplement and is not a substitute for medicine
  • Clearly state the recommended daily intake and suggested timing
  • Identify populations for whom the product is not suitable, such as minors, pregnant or breastfeeding people, and people with autoimmune disease or depression
  • Warn against prolonged continuous use
  • Advise users to avoid driving, working at height, or operating precision equipment after taking the product
  • Instruct users to stop use immediately and consult a qualified professional if discomfort occurs

6. References and Regulatory Sources by Jurisdiction

Note: Specific document numbers and editions must be verified individually before publication.

Mainland China

  • State Administration for Market Regulation (SAMR): Determination of Melatonin in Health Foods (GB/T 45443-2025)
  • State Administration for Market Regulation (SAMR): Announcement No. 58 of 2025 concerning additional dosage forms and excipients for filed health-food products using coenzyme Q10 and melatonin ingredients
  • National Medical Products Administration (NMPA): publicly available educational materials on melatonin health foods

United States

  • U.S. Food and Drug Administration (FDA): publicly available documents on the dietary-supplement regulatory framework

European Union

  • European Food Safety Authority (EFSA): scientific opinions on melatonin health claims reflected in Regulation (EU) No 432/2012, including permitted claims concerning subjective feelings of jet lag and reduction of time to fall asleep

Australia and Canada

  • Therapeutic Goods Administration (TGA), Australia: publicly available regulatory materials concerning melatonin products
  • Health Canada: publicly available regulatory materials concerning natural health products

General Research and Medical References

  • MSD Manual Professional Edition: material related to melatonin, updated July 2025
  • Yale Medicine: “Should You Try Melatonin to Help You Sleep?” (2025)
  • Publicly available basic and clinical research on melatonin and circadian-rhythm regulation

These sources are grouped by jurisdiction and do not constitute guidance applicable to any single jurisdiction. They are used only as sources of technical reference and information. This guide does not incorporate their mandatory provisions and does not represent full compliance with them. Always consult the versions of laws and standards currently in force at the time of use.

Additional Notes

  • This guide is a reference document within the World Sleep Industry Technology System (WSIT) and is provided for professionals in the global sleep industry. It does not certify, recommend, or endorse any product or service and does not replace applicable local laws and regulations.
  • Melatonin requirements differ substantially across countries and regions. Product development, manufacturing, labeling, claims, and sales must comply with the laws currently in force where the product is marketed.
  • Authors and industry-supporting organizations are listed on the contributors page (worldsleep.com/contributors) and supporters page (worldsleep.com/supporters).
  • Actual ingredients, formulation, and functional claims are governed by the product instructions and the laws currently in force where it is marketed.

© 2026 World Sleep Center. All rights reserved.

worldsleep.com

Sources, regulations, and standards are subject to the source document and the versions in force at publication. Product parameters and use requirements are governed by product documentation and applicable local law.